drugset
Drugs / Iron(III)carboxymaltose
last change Apr 2020 re-read 3 minutes ago

Iron(III)carboxymaltose

also known as FCM · ferric carboxymaltose
Developed for
iron deficiency anemia · disorder of iron metabolism and transport
Investigated by
Catharina Ziekenhuis Eindhoven

Trials 1

today NCT02210949 · Ph 4
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT02210949 Aug 2014 → Apr 2017 iron deficiency anemia, postoperative ventricular dysfunction Catharina Ziekenhuis Eindhoven Terminated No outcome recorded
Comparator or background therapy1 trial
Phase 4 NCT02271997 Comparator Dec 2014 → Jun 2017 disorder of iron metabolism and transport Rijnstate Hospital Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as iron(III)carboxymaltose “Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once.” NCT02210949 ↗
1

NCT02271997 ↗
Known as FCM “AIM: To compare the efficacy of oral ferrous fumarate (FF), oral ferrous gluconate (FG), and a single intravenous infusion of ferric carboxymaltose (FCM) in women with ID after RYGB.” PMID 32402684 ↗ Apr 2020
Known as ferric carboxymaltose “AIM: To compare the efficacy of oral ferrous fumarate (FF), oral ferrous gluconate (FG), and a single intravenous infusion of ferric carboxymaltose (FCM) in women with ID after RYGB.” PMID 32402684 ↗ Apr 2020
Route Intravenous “Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once.” NCT02210949 ↗